Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Increased prefrontal cortex activity during negative emotion regulation as a predictor of depression symptom severity trajectory over 6 months.

Heller AS, Johnstone T, Peterson MJ, Kolden GG, Kalin NH, Davidson RJ.

JAMA Psychiatry. 2013 Nov;70(11):1181-9. doi: 10.1001/jamapsychiatry.2013.2430.

2.

Reduced right ventrolateral prefrontal cortex activity while inhibiting positive affect is associated with improvement in hedonic capacity after 8 weeks of antidepressant treatment in major depressive disorder.

Light SN, Heller AS, Johnstone T, Kolden GG, Peterson MJ, Kalin NH, Davidson RJ.

Biol Psychiatry. 2011 Nov 15;70(10):962-8. doi: 10.1016/j.biopsych.2011.06.031. Epub 2011 Aug 25.

3.

Venlafaxine extended-release: a review of its use in the management of major depression.

Wellington K, Perry CM.

CNS Drugs. 2001;15(8):643-69. Review.

PMID:
11524036
4.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
5.

rTMS treatment for depression in Parkinson's disease increases BOLD responses in the left prefrontal cortex.

Cardoso EF, Fregni F, Martins Maia F, Boggio PS, Luis Myczkowski M, Coracini K, Lopes Vieira A, Melo LM, Sato JR, Antonio Marcolin M, Rigonatti SP, Cruz AC Jr, Reis Barbosa E, Amaro E Jr.

Int J Neuropsychopharmacol. 2008 Mar;11(2):173-83. Epub 2007 Aug 21.

PMID:
17708780
6.
7.

Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.

Shelton C, Entsuah R, Padmanabhan SK, Vinall PE.

Int Clin Psychopharmacol. 2005 Jul;20(4):233-8.

PMID:
15933485
8.

Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder.

Hunter AM, Muthén BO, Cook IA, Leuchter AF.

J Psychiatr Res. 2010 Jan;44(2):90-8. doi: 10.1016/j.jpsychires.2009.06.006. Epub 2009 Jul 24.

10.

Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study.

Bares M, Kopecek M, Novak T, Stopkova P, Sos P, Kozeny J, Brunovsky M, Höschl C.

J Affect Disord. 2009 Nov;118(1-3):94-100. doi: 10.1016/j.jad.2009.01.032. Epub 2009 Feb 26.

PMID:
19249105
11.

Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.

Kennedy SH, Andersen HF, Lam RW.

J Psychiatry Neurosci. 2006 Mar;31(2):122-31. Erratum in: J Psychiatry Neurosci. 2006 Jul;31(4):228.

12.

The brain tells: early signs of depression recovery.

[No authors listed]

Harv Ment Health Lett. 2002 Nov;19(5):6. No abstract available.

PMID:
12453746
13.

Medial prefrontal cortex activity during memory encoding of pictures and its relation to symptomatic improvement after citalopram treatment in patients with major depression.

Roy M, Harvey PO, Berlim MT, Mamdani F, Beaulieu MM, Turecki G, Lepage M.

J Psychiatry Neurosci. 2010 May;35(3):152-62. Erratum in: J Psychiatry Neurosci. 2010 Jul;35(4):228.

14.

When depression doesn't lead with depression.

Miller MC.

JAMA Psychiatry. 2013 Nov;70(11):1131-2. doi: 10.1001/jamapsychiatry.2013.3493. No abstract available.

PMID:
24173599
15.

Relationships between changes in sustained fronto-striatal connectivity and positive affect in major depression resulting from antidepressant treatment.

Heller AS, Johnstone T, Light SN, Peterson MJ, Kolden GG, Kalin NH, Davidson RJ.

Am J Psychiatry. 2013 Feb;170(2):197-206. doi: 10.1176/appi.ajp.2012.12010014.

16.

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E.

JAMA. 2000 Jun 21;283(23):3082-8.

PMID:
10865302
17.
18.

Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.

Hewett K, Gee MD, Krishen A, Wunderlich HP, Le Clus A, Evoniuk G, Modell JG.

J Psychopharmacol. 2010 Aug;24(8):1209-16. doi: 10.1177/0269881109106953. Epub 2009 Nov 25.

PMID:
19939870
19.

Effect of bupropion extended release on negative emotion processing in major depressive disorder: a pilot functional magnetic resonance imaging study.

Robertson B, Wang L, Diaz MT, Aiello M, Gersing K, Beyer J, Mukundan S Jr, McCarthy G, Doraiswamy PM.

J Clin Psychiatry. 2007 Feb;68(2):261-7.

PMID:
17335325
20.

The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases.

Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Dunlop BW, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen R, Yan B, Ahmed S, Schmidt M, Ninan PT.

Biol Psychiatry. 2007 Dec 15;62(12):1371-9. Epub 2007 Sep 7. Erratum in: Biol Psychiatry. 2012 Feb 15;71(4):387. Biol Psychiatry. 2008 Apr;63(7):721.

PMID:
17825800

Supplemental Content

Support Center